WEBULL
WebtradeDownload

CVS Health (CVS) Joins 14 Insurers In Medicare Behavioral Health Push

Simply Wall St · 1d ago
  • CVS Health (NYSE:CVS) is joining thirteen other large U.S. insurers in CMS’s ACCESS behavioral health program for Medicare patients.
  • The ACCESS model uses technology tools, including platforms such as CalmiGo, to support behavioral health treatment for eligible beneficiaries.
  • Participation in the CMS initiative positions CVS Health to integrate technology-supported mental health care into its Medicare-focused value-based care offerings.
  • There is more to CVS Health than its decision to join the CMS ACCESS behavioral health program with tools like CalmiGo. Check out 2 warning signs that CVS Health investors should know about.

For readers who want more exposure to technology-supported care and digital tools in medicine, consider exploring 39 healthcare AI stocks.

NYSE:CVS Earnings & Revenue Growth as at Sep 2026
NYSE:CVS Earnings & Revenue Growth as at Sep 2026

CVS Health runs a broad health solutions platform in the US, and this ACC​ESS move plugs technology-supported behavioral care into a business that already touches many Medicare beneficiaries through insurance and pharmacy services.

4 things going right for CVS Health that this headline doesn't cover.

How could ACCESS affect CVS Health’s business model?

The ACCESS program plugs technology supported behavioral care into CVS Health’s Medicare book, which already spans insurance, pharmacy and clinics. That gives the group a test bed for using tools like CalmiGo to extend care beyond the visit, potentially deepening member engagement and creating more touchpoints across its integrated platform.

Does this change the CVS Health Narrative or mostly reinforce it?

This news lines up with the existing Narrative rather than rewriting it. ACCESS leans into two highlighted catalysts: digital health investments and value based care expansion. The flagged risks on medical cost trends, reimbursement pressure and long retail exposure remain in place.

See how these catalysts shape CVS Health's path to a $115 fair value.

What should investors watch next to judge whether ACCESS is moving the needle?

The clearest early test will be how management quantifies ACCESS in Medicare metrics by the 2027 and 2028 reporting cycles, as participating insurers align with the model by 2028. Watch for disclosed enrollment in ACCESS supported behavioral programs, engagement rates with tools like CalmiGo, and any segment commentary that ties these to medical cost or margin trends.

Add CVS Health to your Watchlist and get alerts as these catalysts play out.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.